Personalized Atopic Dermatitis Treatment: Expert Insights from Dr. Armstrong

The landscape of atopic dermatitis (AD) treatment is rapidly evolving, moving beyond a one-size-fits-all approach toward personalized therapies. This shift is driven by a deeper understanding of the disease’s complex underlying mechanisms and the increasing availability of targeted treatments. Leading this charge is Dr. April Armstrong, Professor and Chief of Dermatology at UCLA, whose research focuses on identifying optimal treatment strategies for inflammatory skin diseases like AD, psoriasis and hidradenitis suppurativa (HS).

Understanding Atopic Dermatitis and the Need for Personalization

Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterized by itchy, inflamed skin. It affects millions worldwide, impacting quality of life and often co-occurring with other conditions like asthma and allergic rhinitis. Traditionally, treatment has involved emollients to hydrate the skin and topical corticosteroids to reduce inflammation. However, these approaches don’t always provide sufficient relief, and long-term corticosteroid apply can have side effects. The need for more effective and tailored treatments is clear.

Dr. Armstrong’s operate centers on evaluating both new systemic and topical therapies for inflammatory skin diseases. She has conducted over 150 clinical trials and published over 600 articles in scientific journals, demonstrating a commitment to advancing the field through rigorous research. Her profile on the UCLA Health website details her extensive contributions to understanding and treating these conditions.

The Role of Biomarkers and Targeted Therapies

Personalizing AD treatment involves identifying specific characteristics – or biomarkers – in each patient that can predict their response to different therapies. These biomarkers can include genetic factors, immune system profiles, and the presence of specific inflammatory molecules. For example, the type 2 inflammatory pathway plays a significant role in many AD patients. Targeted therapies, such as biologics that block specific cytokines (immune signaling molecules) within this pathway, have shown promising results.

Dr. Armstrong’s research also focuses on identifying treatment goals and comorbidities associated with skin diseases. Comorbidities – the presence of other conditions alongside AD – can significantly impact treatment outcomes. Addressing these co-existing conditions, such as anxiety or sleep disturbances, is crucial for comprehensive care.

Expanding Access Through Technology

Beyond developing new treatments, Dr. Armstrong is also dedicated to increasing patient access to care. She is exploring innovative, technology-enabled healthcare delivery methods to overcome barriers to access, particularly for patients in underserved communities. This includes leveraging telehealth and remote monitoring technologies to provide convenient and effective care. As Co-Director for Network Resources at the UCLA Clinical and Translational Research Institute, she’s positioned to implement these changes.

The Evolution of Dr. Armstrong’s Research

Prior to her role at UCLA, Dr. Armstrong held leadership positions at the University of Southern California (USC), the University of California Davis, and the University of Colorado. Her UCLA profile highlights her consistent focus on clinical trials and outcomes research throughout her career. This experience has provided her with a broad perspective on the challenges and opportunities in AD treatment.

Clinical Trial Insights and the Importance of Research

Dr. Armstrong’s extensive involvement in clinical trials – over 150 to date – is a cornerstone of her work. These trials are essential for evaluating the safety and efficacy of new treatments before they become widely available. They also help researchers understand which patients are most likely to benefit from specific therapies. The International Psoriasis Council notes her publication of over 350 high-impact articles, demonstrating the breadth of her research contributions.

However, it’s important to remember that clinical trials have limitations. Study populations may not fully represent the diversity of patients with AD, and results may not always translate directly to real-world clinical practice. Correlation does not equal causation; even if a treatment is associated with improvement, it doesn’t necessarily imply the treatment *caused* the improvement.

What’s Next in Atopic Dermatitis Treatment?

The field of atopic dermatitis treatment is poised for continued innovation. Ongoing research is focused on identifying new biomarkers, developing more targeted therapies, and improving access to care. Dr. Armstrong’s work, along with that of other leading researchers, is paving the way for a future where AD treatment is truly personalized, offering hope for improved outcomes and quality of life for millions of patients. Future research will likely focus on refining biomarker identification and developing combination therapies to address the multifaceted nature of AD. Continued monitoring of clinical trial results and real-world data will be crucial for optimizing treatment strategies and ensuring patient safety.